Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit h5n1 vaccine by eliciting high-affinity antibodies

Journal of Virology

Volumn 86, Issue 22, 2012, Pages 12283-12293

  Verma, Swati ^a,b   Dimitrova, Milena ^a   Munjal, Ashok ^b,e   Fontana, Juan ^c   Crevar, Corey J ^d   Carter, Donald M ^d   Ross, Ted M ^d   Khurana, Surender ^a   Goldinga, Hana ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b BANASTHALI UNIVERSITY   (India)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e INDIRA GANDHI NATIONAL TRIBAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT HEMAGGLUTININ 1 VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLADISTICS; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; FERRET; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; NONHUMAN; NOSE PROVOCATION TEST; OLIGOMERIZATION; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE; WILD TYPE;

ANIMALS; ANTIBODIES, NEUTRALIZING; CHROMATOGRAPHY, GEL; DNA, COMPLEMENTARY; ERYTHROCYTES; ESCHERICHIA COLI; FERRETS; HEMAGGLUTINATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEUTRALIZATION TESTS; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; RESPIRATORY SYSTEM; SURFACE PLASMON RESONANCE; VIRAL LOAD;

MUSTELA; ORTHOMYXOVIRIDAE;

EID: 84869128033     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01596-12     Document Type: Article

References (55)

1. Baras B, et al. 2008. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 3:e1401. doi:10.1371/journal.pone.0001401.
2. Bright RA, et al. 2008. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3:e1501. doi:10.1371/journal.pone.0001501.
3. Chen Y, et al. 2009. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J. Infect. Dis. 199:49-58.
4. Cornelissen LA, et al. 2010. A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1. PLoS One 5:e10645. doi:10.1371/journal.pone.0010645.
5. Corti D, et al. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest.120:1663-1673.
6. Crevar CJ, Ross TM. 2008. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol. J. 5:131.
7. de Jong MD, et al. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12:1203-1207.
8. Ekiert DC, et al. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251.
9. Epstein SL. 2006. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957:an experiment of nature. J. Infect. Dis. 193:49-53.
10. Fiore AE, Bridges CB, Cox NJ. 2009. Seasonal influenza vaccines. Curr. Top. Microbiol. Immunol. 333:43-82.
11. Hatta Y, et al. 2010. Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. PLoS Pathog. 6:e1001139. doi:10.1371/journal.ppat.1001139.
12. Heymann JB, Belnap DM. 2007. Bsoft: image processing and molecular modeling for electron microscopy. J. Struct. Biol. 157:3-18.
13. Jabbar MA, Sivasubramanian N, Nayak DP. 1985. Influenza viral (A/WSN/33) hemagglutinin is expressed and glycosylated in the yeast Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U. S. A. 82:2019-2023.
14. Kashyap AK, et al. 2008. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl. Acad. Sci. U. S. A. 105:5986-5991.
15. Khurana S, et al. 2010. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2:15ra5. doi:10.1126/scitranslmed.3000624.
16. Khurana S, et al. 2011. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine 29:5657-5665.
17. Khurana S, et al. 2009. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 6:e1000049. doi:10.1371/journal.pmed.1000049.
18. Khurana S, Verma N, Talaat KR, Karron RA, Golding H. 2012. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J. Infect. Dis. 205:610-620.
19. Khurana S, et al. 2011. MF59 Adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.Sci. Transl. Med. 3:85ra48. doi:10.1126/scitranslmed.3002336.
20. Khurana S, et al. 2011. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J. Virol. 85:1246-1256.
21. Khurana S, et al. 2010. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS One 5:e11548. doi:10.1371/ journal.pone.0011548.
22. Khurana S, et al. 2011. H5N1 virus-like particle vaccine elicits crossreactive neutralizing antibodies in humans that preferentially bind to oligomeric form of influenza hemagglutinin. J. Virol. 85:10945-10954.
23. King JC, Jr, et al. 2009. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 27:6589-6594.
24. Krause JC, et al. 2011. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J. Virol. 85:10905-10908.
25. Lin SC, et al. 2011. Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS One 6:e20052. doi:10.1371/journal.pone.0020052.
26. Lipatov AS, Hoffmann E, Salomon R, Yen HL, Webster RG. 2006.Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J. Infect. Dis. 194:1040-1043.
27. Lu H, et al. 2011. A rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin vaccine immunogen in mammalian cells. PLoS One 6:e17297. doi:10.1371/journal.pone.0017297.
28. Ludtke SJ, Baldwin PR, Chiu W. 1999. EMAN: semiautomated software for high-resolution single-particle reconstructions. J. Struct. Biol. 128:82-97.
29. Maher JA, DeStefano J. 2004. The ferret: an animal model to study influenza virus. Lab Anim. (NY) 33:50-53.
30. Mahmood K, et al. 2008. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26:5393-5399.
31. McKinstry KK, et al. 2012. Memory CD4+T cells protect against influenza through multiple synergizing mechanisms. J. Clin. Invest. 122:2847-2856.
32. Monsalvo AC, et al. 2011. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat. Med. 17:195-199.
33. Monto AS. 2006. Vaccines and antiviral drugs in pandemic preparedness.Emerg. Infect. Dis. 12:55-60.
34. Ohmit SE, et al. 2006. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N.Engl. J. Med. 355:2513-2522.
35. Okuno Y, Isegawa Y, Sasao F, Ueda S. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67:2552-2558.
36. Pierce SK, Liu W. 2010. The tipping points in the initiation of B cell signalling: how small changes make big differences. Nat. Rev. Immunol.10:767-777.
37. Ruigrok RW, et al. 1986. Electron microscopy of the low pH structure of influenza virus haemagglutinin. EMBO J. 5:41-49.
38. Shaikh TR, et al. 2008. SPIDER image processing for single-particle reconstruction of biological macromolecules from electron micrographs.Nat. Protoc. 3:1941-1974.
39. Shen S, et al. 2008. Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria. J. Med. Virol. 80:1972-1983.
40. Shoji Y, et al. 2010. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum. Vaccine 7(Suppl):41-50.
41. Smith GJ, et al. 2006. Emergence and predominance of an H5N1 influenza variant in China. Proc. Natl. Acad. Sci. U. S. A. 103:16936-16941.
42. Suguitan AL, Jr et al. 2006. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med.3:e360. doi:10.1371/journal.pmed.0030360
43. Sui J, et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol.Biol. 16:265-273.
44. Tao P, et al. 2009. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol. 22:273-281.
45. To KK, et al. 2010. Viral load in patients infected with pandemic H1N1 2009 influenza A virus. J. Med. Virol. 82:1-7.
46. To KK, et al. 2010. Delayed clearance of viral load and marked cytokine Verma et al. activation in severe cases of pandemic H1N1 2009 influenza virus infection.Clin. Infect. Dis. 50:850-859.
47. Treanor JJ, et al. 1996. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.J. Infect. Dis. 173:1467-1470.
48. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.N. Engl. J. Med. 354:1343-1351.
49. van Riel D, et al. 2007. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am. J.Pathol. 171:1215-1223.
50. Verma N, et al. 2012. Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 domain) in the elderly than in young adults and children. J. Virol. 86:5515-5522.
51. Wei CJ, et al. 2008. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol. 82:6200-6208.
52. Weldon WC, et al. 2010. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 5:e12466. doi:10.1371/journal.pone.0012466.
53. Whittle JR, et al. 2011. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc.Natl. Acad. Sci. U. S. A. 108:14216-14221.
54. Yoshida R, et al. 2009. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 5:e1000350. doi:10.1371/journal.ppat.1000350.
55. Zitzow LA, et al. 2002. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J. Virol. 76:4420-4429.